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In the forthcoming era of cancer gene therapy, efforts will be devoted to the development of new efﬁcient
and non-toxic gene delivery vectors. In this regard, the use of Fmoc/Boc-protected oligo(ethane amino)
acids as building blocks for solid-phase-supported assembly represents a novel promising approach
towards fully controlled syntheses of effective gene vectors. Here we report on the synthesis of deﬁned
polymers containing the following: (i) a plasmid DNA (pDNA) binding domain of eight succinoyl-
tetraethylenpentamine (Stp) units and two terminal cysteine residues; (ii) a central polyethylene glycol
(PEG) chain (with twenty-four oxyethylene units) for shielding; and (iii) speciﬁc peptides for targeting
towards cancer cells. Peptides B6 and c(RGDfK), which bind transferrin receptor and αvβ3 integrin,
respectively, were chosen because of the high expression of these receptors in many tumoral cells. This
study shows the feasibility of designing these kinds of fully controlled vectors and their success for
targeted pDNA-based gene transfer.
Introduction
Cancer is one of the most aggressive diseases known, and
surgery and conventional chemotherapy often do not provide sat-
isfactory therapeutic beneﬁt. In the case of metastasis, tumor-
targeted gene therapies would be highly desirable to introduce
lethal genes into tumors, thereby inducing apoptosis or immune
responses or blocking neoangiogenesis. Receptor-targeted syn-
thetic gene delivery methods1–4 appear to be a promising sol-
ution; however, their chemistry and biological efﬁciency require
further improvement.
Many kinds of polymers for the delivery of nucleic acids into
cells have been developed since 1962 (ﬁrst application: delivery
of infectious poliovirus RNA).5–7 Receptor-mediated DNA
delivery by targeting polymer conjugates was ﬁrst introduced by
Wu and Wu in 1987.8 Asialoglycoprotein–polylysine conjugates
were used for the formation of so-called polyplexes9 by the elec-
trostatic interaction of a negatively charged plasmid DNA
(pDNA) and the polycationic polymer. In this form, pDNA was
protected from degradation in the blood and targeted for in vivo
expression in hepatocytes. Nevertheless, polyplex uptake into
the cells by the endocytic pathway poses a signiﬁcant problem:
entrapment in the endolysosomal compartment strongly limits
the efﬁciency of polyplexes. Endosomal release was ameliorated
by introduction of lysosomotropic agents such as chloroquine,10
endosomolytic peptides,10,11 or with polymers such as polyethy-
lenimine (PEI)12 with inherent endosomal-escape properties.
The “proton sponge” effect13–16 of PEI, namely the buffering
capacity between neutral and endosomal pH contributes to the
destabilization of endosomes and release of polyplexes into the
cytosol. Thus, PEI is one of the most advantageous, commonly
used cationic transfection polymers. However, there are several
aspects where further optimization of PEI-like polymers can be
considered. Improved biocompatibility of PEI would be
beneﬁcial; PEI of various molecular weights and structures may
induce membrane damage when present at higher concentrations,
thus causing cell death by apoptosis.17,18 Also interactions with
blood cells19 and activation of the complement system20
decrease biocompatibility, efﬁciency, and target speciﬁcity. In
this regard, effort has been made to reduce the toxicity of PEI
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without decreasing its beneﬁts in gene transfer. As toxicity is
correlated with polymer size, biodegradable PEI analogs that
degrade into non-toxic smaller fragments have been
developed.21–23 Other strategies focus on targeting moieties and
surface shielding of polyplexes using polyethylene glycol (PEG)
bound to PEI,24,25 in some cases by pH-sensitive linkers.26,27
Like many other conventional polymers, another limitation of
PEI is the inherent polydispersity in molecular weight and the
heterogeneity of modiﬁcation sites in chemical conjugates. One
solution to overcome this limitation would be the use of solid-
phase peptide synthesis (SPPS) methodologies, but using
deﬁned oligoamine building blocks instead of amino acids. In
this regard Hartmann and colleagues28–30 generated precise,
sequence-deﬁned cationic polymers for pDNA polyplex for-
mation. We adapted this strategy by designing novel Fmoc/Boc-
protected oligo(ethane amino)acids as building blocks.31 These
blocks are fully compatible with SPPS conditions and contain
oligoethylenimine motifs, which are considered responsible for
the high efﬁciency of PEI. In a proof of concept study, we syn-
thesized a polymer library of highly pure monodisperse poly-
mers with full control of their chemical composition and
structure.32 Several polymer candidates showed high transfection
efﬁcacy for DNA and siRNA delivery and low toxicity.32
Here we provide the ﬁrst description of the synthesis of
precise peptide–PEG–oligo(ethane amino)amide polymers and
their successful use in receptor-targeted, surface-shielded pDNA
polyplexes. We tested two examples of tumor-targeting peptides
which speciﬁcally recognize receptors that are highly expressed
in tumor cells. These peptides were B6 peptide
(GHKAKGPRK), which binds to the transferrin receptor,33 and
c(RGDfK), which binds with high afﬁnity and selectivity to αvβ3
integrin.34–36 Targeting peptides were attached at one end of a
monodisperse PEG molecule as shielding moiety. The oligo
(ethane amino)amide polycation for pDNA binding and conden-
sation was linked in a T-shape conﬁguration to the other end of
the PEG chain (Fig. 1). Terminal cysteine residues were included
for polyplex stabilization by disulﬁde bond formation. The poly-
meric constructs were synthesized on solid phase and their
efﬁcacy in receptor-speciﬁc pDNA transfer was successfully
demonstrated in two tumor cell lines.
Results and discussion
Peptide and polymer synthesis
The objective of this study was to design targeted polymers for
pDNA delivery following a fully controlled and precise synthetic
methodology, and to evaluate the biological proﬁle of these
structures in cell culture as a ﬁrst approach for targeting DNA
delivery in vivo. For this purpose, we designed four polymers
that share the same polymeric scaffold but present distinct target-
ing peptides (Fig. 1). These molecules consist (from C- to N-
terminus) of a targeting or negative control peptide, a precise
PEG moiety for shielding that contains 24 oxyethylene units, a
branching unit (lysine) extended by the nucleic acid binding
domain with four succinoyl-tetraethylenpentamine (Stp) units,31
and terminal cysteine residues at the end of the two Stp4 arms.
The Stp units refer to the novel oligo(ethane amino)amide build-
ing blocks for pDNA binding.31 These Stp units were added
sequentially in their Fmoc/Boc-protected form to the growing
polymer chain using conventional SPPS protocols. Concerning
the targeting sequences, two bioactive epitopes were chosen
(Fig. 1, structures B6 and c(RGDfK)). The B6 peptide33
(GHKAKGPRK) targets the human transferrin receptor (hTfR),
which is overexpressed in various cancers, and has already been
successfully applied in targeted polyplexes.37–39 RGD is a well-
known recognition motif that binds to integrins,40,41 and these
receptors are overexpressed in many tumor cell types and tumor
vasculature.42 The cyclic RGD peptide c(RGDfK)34,36 shows
high afﬁnity and selectivity for αvβ3 integrin.
43 Both
integrins25,44–49 and TfR49–53 have been successfully evaluated
as suitable targets for nucleic acid delivery to cancer cells. As
inactive controls, we used either a modiﬁed peptide derived from
B6 (B6mod, where lysine and arginine residues are replaced by
glycine, GHGAGGPGG) or, instead of the cyclic RGD peptide,
the simple amino acid residue alanine (Fig. 1, structures B6mod
and Ala).
B6, B6mod and Ala polymers ((C-Stp4)2-K-PEG-B6,
(C-Stp4)2-PEG-B6mod and (C-Stp4)2-PEG-A, respectively) were
assembled stepwise on solid-phase. Alternatively, the c(RGDfK)
polymer ((C-Stp4)2-K-PEG-A-c(RGDfK)) was obtained via
coupling in solution of the conveniently protected cyclic RGD
peptide and the polymeric scaffold, both previously prepared
Fig. 1 Chemical structure of polymers prepared. Stp = succinoyl-tetra-
ethylenpentamine units; PEG = polyethylene glycol units; X = peptide
motif: B6, transferrin-receptor targeting polymer (C-Stp4)2-K-PEG-B6;
B6mod, transferrin-receptor targeting negative control polymer
(C-Stp4)2-K-PEG-B6mod; c(RGDfK), αvβ3-targeting polymer (C-Stp4)2-
K-PEG-A-cRGDfK; Ala, negative control polymer (C-Stp4)2-K-PEG-A.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 3258–3268 | 3259
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using SPPS (see Materials and methods section for further
details). Each polymer was characterized by 1H-NMR,
RP-HPLC and mass spectrometry (Fig. S1–S6, ESI†).
Polyplex characterization
Having synthesized and characterized the polymers, we studied
the characteristics of their interaction with the pDNA in order to
gain a better knowledge of the nature of these new gene delivery
vectors. Polyplexes were formed at a range of polymer/pDNA
ratios deﬁned by protonable nitrogen/phosphate molar ratios
(N/P ratios), using ﬁxed amounts of pDNA (pCMVeGFPLuc,
200 ng). The agarose gel shift assay displayed in Fig. 2 shows
the pDNA binding capacity of the B6, c(RGDfK), B6mod and
Ala polymers at the N/P ratios tested. All the polymers retained
pDNA at a N/P ratio of 20, thereby indicating satisfactory pDNA
binding, which is essential for their transfection efﬁcacy. B6
polymer retains pDNA better than the other polymers, probably
due to the presence of positively charged residues in its
sequence. This issue will be further discussed in the following
sections. The particle size and structure of the polyplexes were
analyzed by transmission electron microscopy (TEM) (Fig. 3),
atomic force microscopy (AFM) (Fig. 4) and dynamic light scat-
tering (DLS) (Fig. S7, ESI†). Polyplexes at a N/P ratio of 20
adopted a “doughnut” shape measuring around 70–100 nm in
Fig. 2 pDNA binding capacity of B6, B6mod, c(RGDfK) and Ala
polymers as determined by means of an agarose gel shift assay at a
range of N/P ratios (3 : 1, 6 : 1, 12 : 1 and 20 : 1). pDNA polyplex for-
mation was performed following transfection conditions (30 min of
incubation in HEPES-buffered glucose (HBG)).
Fig. 3 Upper panel: TEM images of polyplexes (N/P ratio of 20 : 1) placed on a carbon ﬁlm-coated copper grid and stained with 2% uranyl acetate
(A, C, E and G). Lower panel: TEM images of the replica obtained after freeze-ﬁxation and freeze-drying of a 50 mm aqueous solution of polyplexes
at a N/P ratio of 20 (B, D, F and H) on an uncoated coverslip. (I) is a replica obtained after freeze-ﬁxation and freeze-drying of free pDNA. Scale bars
shown are of either 200 nm (for E, B, F and H) or 500 nm (for A, C, D, G and I). (A) and (B) correspond to B6 polyplex; (C) and (D) to B6mod poly-
plex; (E) and (F) to c(RGDfK) polyplex; (G) and (H) to Ala polyplex; (I) is free pDNA.
Fig. 4 AFM images of polyplexes (N/P ratio of 20 : 1) placed on a
mica surface and dried RT for 5–10 min. (A) B6 polyplex; (B) B6mod
polyplex; (C) c(RGDfK) polyplex; (D) Ala polyplex.
3260 | Org. Biomol. Chem., 2012, 10, 3258–3268 This journal is © The Royal Society of Chemistry 2012
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diameter. The upper images in Fig. 3(A), (C), (E) and (G) show
dried polyplexes stained with uranyl acetate. Some other of these
structures adopted a more “rod-like” shape. In Fig. 3 lower
images (B), (D), (F) and (H) the same polyplexes were freeze-
dried, keeping the shape and structure as they appear in solution.
From these images it can be inferred that the preferred shape of
the polyplexes is the “doughnut” shape, a common conﬁguration
of several pDNA–polycation polyplexes.54 Fig. 3I shows a
freeze-dried replica of pDNA alone. The rounded shape is much
larger (around 350 nm) than that of the polyplexes (70–100 nm),
indicating a clear compaction of the pDNA when the polymers
are present. However, this compaction was not maximal with the
PEG-containing polymers. The analogous polyplexes formed
with pDNA and Ala polymer lacking PEG moiety, (C-Stp4)2-
K-A, showed a more compact shape of around 40 nm (see
Fig. S8, ESI†). Presumably and not surprisingly, the high
content of PEG (24 monomer units compared to 8 Stp units, i.e.
24 protonable ethane amino units) in the targeting polymers
interfered with pDNA condensation, resulting in more loose
‘spaghetti-type’ nanostructures. AFM images are consistent with
the results obtained by TEM (Fig. 4). Dried polyplexes at the
same N/P ratio on a mica surface showed similar shapes and
polyplex sizes as those observed by TEM. Furthermore, DLS
was used to determine polyplex size and also zeta potential (see
Fig. S7, ESI†). DLS data are well in agreement with TEM and
AFM; the apparent high polydispersity index PDI of 0.2–0.5
does not correlate with the observed homogeneity but is consist-
ent with the fact that particles are not fully compacted into solid
spheres because of the high PEG content. DLS of uncomplexed
polymers without pDNA did not show detectable nanostructures
in water for all four ligand–PEG polymers (data not shown),
which is in line with their largely hydrophilic character. Poly-
plexes containing polymer and a PEG moiety in their structure
(with the exception of B6 polymer) showed a zeta potential of
nearly zero, indicating almost no charge on their surface. The
PEG moiety acts as a “charge-shielding moiety”, which may
prevent non-speciﬁc interactions between the polyplex and the
negatively charged cell surfaces. In contrast, the zeta potential of
polyplexes containing B6 polymer was around +12 to 15 mV at
N/P ratios of 6 to 20 (see Fig. S7, ESI†). This ﬁnding can be
explained by the presence of the positive amino acid residues of
the B6 sequence, which might be responsible for some non-
speciﬁc interactions of B6-polyplexes with cells (see below).
Our structures contained two terminal cysteine residues at the
end of each polymeric branch (Fig. 1). The presence of these
residues in related peptide-based gene delivery vectors improves
pDNA complexation and thus its delivery efﬁciency.55–57 This
improvement has also been demonstrated in our recent study
with Stp-based non-targeted polyplexes32. Disulﬁde bridge for-
mation is thought to be relevant in the stabilization of poly-
plexes, as these bridges can further increase polyplex
compaction by forming a surrounding “cage”. Polyplexes would
then be stabilized not only by electrostatic interactions but also
by the presence of disulﬁde bridges. Our cysteine-containing
polymers showed accelerated disulﬁde bridge formation in the
presence of pDNA (Fig. 5), which is consistent with previously
published work on template-assisted oligomerization.32,58,59 The
presence of DNA catalyzed the formation of disulﬁde bridges, as
the local concentration of free thiols was greatly increased as a
result of the electrostatic interactions between the negatively
charged DNA and the cationic polymer.
Transfection efﬁcacy
After studying the biophysical aspects of the polyplexes, we
assessed the capacity of these polymers to deliver pDNA into
the cells in a receptor-speciﬁc way. The high PEG content of the
polyplexes should reduce non-speciﬁc internalization by shield-
ing positive charges of the polymer backbone from the polyplex
surface. Thus unspeciﬁc interactions of the polyplex backbone
with the negative glycocalix of the cells should be reduced.
When the peptide moiety is unsuitable for receptor binding, cell
binding and endocytosis should be low. After endocytosis, the
polyplex must escape from the endosome and deliver the pDNA
to the nucleus where gene expression starts to take place. For the
targeting studies, we used mouse neuroblastoma (N2A) and
human prostate adenocarcinoma (DU-145) cells. These are
tumor cell lines that overexpress both TfR60,61 (for B6 peptide
binding) and integrins49 (for c(RGDfK) binding).
The transfection efﬁciency of pDNA polyplexes was tested by
a standard luciferase gene transfer assay. A ﬁxed amount of
pDNA (200 ng, pCMVeGFPLuc) was complexed with the poly-
mers at the indicated N/P molar ratios. Fig. 6 shows the lucifer-
ase gene transfer activity of B6 and B6mod polymers in N2A
and DU-145 cells. Polyplexes at various N/P ratios (6, 12 and
20) were incubated with cells for 1 h. The medium was removed
afterwards and cells were washed with PBS. When indicated, a
concentration of 100 μM of chloroquine was added to the
medium in order to enhance the endosomal escape of the poly-
plexes, as chloroquine is a commonly used endolysosomotropic
weak base. By accumulating in endolysosomes and buffering
pH, chloroquine triggers osmotic effects that promote an
increased release of entrapped drugs or non-viral vectors into the
Fig. 5 DNA-template mediated acceleration of disulﬁde-bridge for-
mation. Detection of free thiol groups over time as an indicator of
disulﬁde formation in the absence or presence of pEGFPLuc DNA
(“DNA”). Polymer solutions or corresponding pDNA polyplexes
polymer/pDNA ratio of N/P 12 in HBG were incubated at room temp-
erature (RT). At the indicated time points, 10 μL of the solutions were
diluted with Ellman’s buffer and DNTB stock solution. The samples
were then measured at 412 nm. The 100% value represents the concen-
tration of the cysteine mercapto group of the polymer at the starting
point.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 3258–3268 | 3261
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cytosol.50,62 The addition of this endosomolytic agent strongly
(by >2 log units) enhanced the activity of B6-bearing polyplexes
compared with the transfection efﬁcacy of polyplexes carrying
the modiﬁed version of B6 peptide (Fig. 6A and B). The
addition of chloroquine was an essential step for these vectors to
be effective, but it also induces signiﬁcant cytotoxicity (see
Fig. S9–S12, ESI†, for the MTT assays). In order to further
demonstrate the capacity of the targeting polymers to effectively
deliver pDNA to the cells, we chose another recently developed
less cytotoxic endosomolytic agent (succinylated polyethyleni-
mine, suc-PEI) to induce polyplex release from the endosomes
(Fig. 6C and D). Suc-PEI has endosomal proton buffering
capacity but is less toxic than PEI. This agent can also be added
to transfections separately from the transfection polyplexes.63
Consistent with the effect of chloroquine, suc-PEI increased the
transfection efﬁcacy of the polyplexes by more than 1000-fold.
Once again, the targeting polyplexes were more than 100 times
more effective than the controls in the presence of this endo-
somolytic agent. But remarkably, suc-PEI showed lower toxicity
than chloroquine (see Fig. S9–S12, ESI†, for the MTT assays).
The optimum gene transfection results were observed at a N/P
ratio of 20 in the case of N2A cells and at a N/P ratio of 6 in the
case of Du-145 cells. These differences are attributed to the indi-
vidual characteristics of each cell line, as particle size is not sig-
niﬁcantly different (see ESI† for DLS data).
We then addressed whether these ﬁndings are also relevant for
another ligand–receptor pair with potential in tumor targeting.
For this purpose we chose the c(RGDfK) peptide as a very
speciﬁc high-afﬁnity ligand for αvβ3 integrins, which are over-
expressed in tumor tissue and tumor cells. αvβ3 integrin is also
overexpressed in N2A and DU-145 cells. Transfection of
DU-145 cells with c(RGDfK) or Ala polyplexes at various N/P
ratios (Fig. 7A) highlighted the effect of the integrin ligand. In
the presence of chloroquine, luciferase expression was enhanced
in cells incubated with c(RGDfK), reaching 1400-fold higher
expression over the Ala control polyplexes. The transfection
efﬁcacy of polyplexes containing the c(RGDfK) peptide was 70
times higher than that of linear PEI (LPEI) polyplexes. The
transfection results in N2A cells (Fig. 7B) or DU-145 cells
(Fig. 7C) in the presence of suc-PEI gave the same results. The
c(RGDfK) polymer achieved up to 1000-fold higher expression
levels than the ligand-free PEGylated control polyplex. Again,
the toxicity of suc-PEI was found to be lower than that of chloro-
quine (see Fig. S9–S12, ESI†).
With the aim to further demonstrate the speciﬁcity of the
binding of these polyplexes to their receptors, we performed
receptor blocking experiments. DU-145 cells were treated either
with free iron-loaded transferrin or with the super potent integrin
antagonist RGD peptide cilengitide64,65 prior to transfection, in
order to block their cell-surface expressed speciﬁc receptors
Fig. 6 Transfection of N2A (A, C) and DU-145 (B, D) cells with pDNA-B6 and B6mod polyplexes at 6, 12 and 20 N/P ratios. After a 1 h incubation
at 37 °C and 5% CO2, medium was removed and replaced by fresh one. Where indicated, 100 μM chloroquine was added in (A) and (B) or 0.8 μg
suc-PEI/well was added in (C) and (D) as described in Materials and methods. Linear polyethylenimine (LPEI) was used as a positive control and
HBG as a negative one.
3262 | Org. Biomol. Chem., 2012, 10, 3258–3268 This journal is © The Royal Society of Chemistry 2012
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(TfR and αvβ3 integrin, respectively) and to prevent polyplex
internalization, thereby demonstrating the speciﬁcity of the con-
structs. DU-145 cells treated with free transferrin for competitive
inhibition of B6 polyplex binding showed a 7-, 6- or 5-fold
decrease in the B6 polyplex-mediated transfection levels, at a
N/P ratio of 6, 12 and 20, respectively (Fig. 8A). Transferrin
competition did not restore expression to the background levels
of the B6mod polyplexes, most probably because of the cationic
nature of the B6 ligand, which – in contrast to the other PEG-
shielded polyplexes – results in a positive zeta potential (see
Fig. S7, ESI†) and triggers moderate cell interaction that is not
dependent on the TfR. Furthermore, competition experiments
using a ﬁxed amount of B6 polyplexes (N/P = 6) and increasing
concentrations of free transferrin (0, 20 and 50 mol equivalents)
were performed in DU-145 and N2A cells (see Fig. S13, ESI†).
When chloroquine was also present, we detected an increasing
reduction of luciferase expression with rising amounts of free
transferrin (10-fold or 3-fold reduction of the B6 polyplex
mediated transfection levels in N2A or DU-145 cells, respect-
ively). Again, background expression levels were not reached
due to the positives charges of B6, as expected, but a TfR-com-
petition effect on gene expression was observed in both cell
lines.
In the case of the c(RGDfK) polymer, a higher reduction of c
(RGDfK)-mediated transfection was observed when cells were
ﬁrst incubated with cilengitide (Fig. 8B). In this case, at a N/P
ratio of 12, competitive inhibition of cilengitide resulted in
nearly 30-fold decrease in luciferase expression (and 3- or 6-fold
reduction for N/P 6 and 20, respectively). Here, cilengitide com-
petition decreased gene expression to almost background levels,
thereby indicating very low non-speciﬁc cell internalization. The
speciﬁc character of this internalization was also conﬁrmed by
zeta potential measurements for c(RGDfK) polyplex, which
revealed that these polyplexes did not carry a surface charge (see
Fig. S7, ESI†). Taken together, these results further validate the
concept of TfR- and αvβ3-targeted gene delivery in the presence
of an endosomolytic agent such as chloroquine. Moreover, cilen-
gitide competition experiments using LPEI showed no
Fig. 7 Transfection of DU-145 (A, C) or N2A (B) cells with c
(RGDfK) or Ala polyplexes. After 1 h incubation at 37 °C and 5% CO2,
medium was removed and replaced by fresh one. Where indicated,
100 μM chloroquine was added in (A) or 0.8 μg suc-PEI/well was added
in (B, C) as described in Materials and methods. LPEI used as a positive
control and HBG as a negative one.
Fig. 8 Receptor blocking assays in DU-145 cells by (A) the soluble
transferrin protein (+Transferrin) with B6 polyplexes, and (B) soluble
cilengitide (+RGD) with c(RGDfK) polyplexes. Cells were treated
where indicated with the free molecules for 10 min at 4 °C to allow
binding on the transferrin receptor (TfR) or αvβ3. Polyplexes at the indi-
cated N/P ratio were then added to the cells. After 1 h of polyplex incu-
bation at 37 °C and 5% CO2, medium was removed and replaced by a
fresh one. In all the cases 100 μM chloroquine was added, as described
in Materials and methods. LPEI was used as a positive control and HBG
as a negative one.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 3258–3268 | 3263
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competitive effect, in contrast with observations in c(RGDfK)
polyplex transfection (Fig. S14, ESI†).
The positive ligand effect observed on polyplex transfection is
very encouraging for the further development of deﬁned poly-
mers based on oligo(ethane amino)amide building blocks.
However, all these data show that the polyplexes tested are
strictly dependent on help by endosomolytic agents. This obser-
vation is not surprising as endosomal release is one of the major
bottlenecks in the intracellular delivery ﬁeld.66 Erythrocyte lysis
assays did not show any detectable lytic activity of the polymers
at any pH (see Fig. S15, ESI†). The current Stp polymers,
however, do contain protonable ethane amino units similar to
PEI. Non-targeted, non-PEGylated Stp-based polymers have
been shown to mediate high gene transfer activity in the absence
of endosomal release agents.32 In contrast, the new-targeted
polymers presented in the current study have a very high PEG
content (equal numbers of protonable ethylenimine units as
ethylene glycol units). This feature has not only been shown to
shield polyplexes but also to inactivate endosomal release of
PEI-based polyplexes.26 Therefore other methods should be con-
sidered to promote endosomal escape, by either enhancing the
proton sponge effect of the targeting polymer or introducing
another endosomolytic function into the polymer such as acid
labile groups between PEG and carrier polymer26,27 or endo-
somolytic peptides.6,10,11 Nevertheless, our current results show
the feasibility of designing newly deﬁned, non-toxic polymers
for receptor-targeted gene delivery.
Conclusions
Here we designed two fully synthetic polymers for receptor-
targeted pDNA transfection. Solid-phase supported synthesis
using novel building blocks provided full control of the sequence
and composition of each polymer. This approach enabled the
generation of precise multidomain polymers containing the fol-
lowing: (i) a peptidic targeting ligand; (ii) a precise PEG shield-
ing molecule; (iii) oligo(ethane amino)amides for pDNA
binding; and (iv) terminal cysteine residues for disulﬁde bridge-
driven stabilization. Peptide ligands targeting the TfR or αvβ3
integrins were examined. Targeting polymers in combination
with endosomolytic agents mediated strongly ligand-dependent
gene transfer in receptor-overexpressing tumor cells. Efforts
devoted to the further development of this targeted and shielded
precise carrier are now centered on the bottleneck of endosomal
escape, which continues to be a major challenge in the ﬁeld of
intracellular gene delivery.
Materials and methods
Materials
Fmoc-Nα-protected amino acids were obtained from IRIS
Biotech GmbH (Marktredwitz, Germany). Fmoc-N-amido-
dPEG®24-acid was obtained from Quanta Biodesign (Ohio,
USA); Stp units were synthesized as described before.31 The 2-
chlorotrityl chloride resin was purchased from IRIS Biotech
GmbH (Marktredwitz, Germany). Coupling reagents: benzotria-
zol-1-yloxytris(pyrrolidino)phosphonium hexaﬂuorophosphate
(PyBOP) was from Novabiochem (Laüfelﬁngen, Switzerland);
1-hydroxy-7-azabenzotriazole (HOAt) was from GL Biochem
(Shanghai, China); 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl-
uronium tetraﬂuoroborate (TBTU) was from Albatros Chem, Inc.
(Montreal, Canada); (2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexaﬂuorophosphate) (HATU) was from
Medalchemy (Alicante, Spain). Triﬂuoroacetic acid (TFA) was
purchased from Scharlab S.L. (Barcelona, Spain); piperidine
from SDS (Peypin, France), dimethylformamide (DMF) from
IRIS Biotech GmbH (Marktredwitz, Germany) and dichloro-
methane (DCM) and acetonitrile (MeCN) from Sigma
(St. Louis, MO). N,N-Diisopropylethylamine (DIEA) was
obtained from Merck (Darmstadt, Germany) and hexaﬂuoroiso-
propanol (HFIP) from Sigma (St. Louis, MO). Triisopropylsilane
(TIS) was from Fluka (Buchs, Switzerland). Heparin sodium salt
from porcine intestinal mucosa (MW = 17–19 kDa) was from
Sigma (St. Louis, MO); GelRed was obtained from Biotium
(Hayward, USA); 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB)
was from Merck (Darmstadt, Germany) and agarose was sup-
plied by Invitrogen (Darmstadt, Germany).
Polymer synthesis
B6- (peptide sequence: GHKAKGPRK), B6mod- (peptide
sequence: GHGAGGPGG), and Ala (C-Stp4)2-K-PEG polymers
were synthesized following standard SPPS procedures using an
orthogonal Fmoc/tBu strategy and L-amino acids. A precise
bifunctional Fmoc-N-amido-dPEG®24-acid and the novel Boc/
Fmoc artiﬁcial oligoamino acid building blocks (succinoyl tetra-
ethylene pentamine (Stp)31) were introduced under the same
conditions. The solid support was 2-chlorotrityl chloride resin in
a scale between 20 and 150 μmol using a 2 mL or 5 mL syringe
reactor (Multisynthec GmbH, Witten, Germany), each ﬁtted with
a polyethylene porous disk. Solid-phase peptide elongation and
other solid-phase manipulations were carried out at room temp-
erature (RT), and solvents and soluble reagents were removed by
suction. Washing procedures between synthesis steps were per-
formed with DMF (5 × 30 s) and DCM (5 × 30 s) using 5 mL
solvent per gram of resin. During couplings the mixture was
allowed to react with intermittent manual stirring. For the c
(RGDfK) polymer, the peptide and the polymeric body were
synthesized separately in a fully protected form and coupled
afterwards in solution. The protected cyclic peptide c(-Arg(Pbf)-
Gly-Asp(OtBu)-D-Phe-Lys-) was synthesized manually in solid-
phase following previously described methods.34,35 For the syn-
thesis of the polymer–c(RGDfK) conjugate, the protected poly-
meric scaffold ([Cys(Trt)-(Stp(Boc3))4]2-Lys-PEG-Ala) (1.1
equiv.), HATU (1.2 equiv.) and HOAt (1.2 equiv.) were dis-
solved in anhydrous DMF to reach a concentration of 0.02 mM.
After the addition of DIEA (5 equiv.), the mixture was pre-acti-
vated for 4 h. Next, c(-Arg(Pbf )-Gly-Asp(OtBu)-D-Phe-Lys-) (1
equiv.) dissolved in the minimum volume of anhydrous DMF
was added to the reaction mixture dropwise and the solution was
stirred for one week at RT. After this time, DMF was evaporated
to dryness, and a saturated solution of NaHCO3 was added to the
crude product, which was then extracted three times with EtOAc.
The organic phase was washed with brine and dried with
Na2SO4. After evaporation, the polymer–c(RGDfK) conjugate
was obtained free of coupling reagents. To remove side chain
3264 | Org. Biomol. Chem., 2012, 10, 3258–3268 This journal is © The Royal Society of Chemistry 2012
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protecting groups, the polymer construct was treated for 3 h with
TFA–H2O–TIS (95 : 2.5 : 2.5, v/v/v) at RT. Next, the compound
was precipitated with cold anhydrous Et2O, centrifuged for
10 min at 4000 rpm, washed twice with this solvent and ﬁnally
redissolved in water and lyophilized.
Initial conditioning of resin. 2-Chlorotrityl chloride resin was
used in all cases and conditioned by swelling in DCM (15 min).
The ﬁrst Fmoc-amino acid (0.7 equiv.) was then attached to the
resin with DIEA (7 equiv.) in DCM (2 mL) for 1 h, without ﬁl-
tration. The remaining active positions were capped by methanol
(0.8 mL g−1 of resin) for 15 min. The resin was ﬁltered and
washed with DCM (5 × 30 s). The Fmoc group was removed,
and ﬁltrates were collected and measured by UV spectroscopy to
determine the loading capacity (0.6 mmol g−1).
Fmoc group removal. To remove the Fmoc group, we treated
the resin with piperidine in DMF (1 : 4 (v/v), 3–4 mL g−1 resin,
1 × 1 min and 2 × 10 min).
Elongation. Couplings of polyamine building blocks (Stp),
deﬁned PEG or amino acids were done by dissolving 4 equiv. of
the Fmoc-protected version of them, PyBOP–HOBt (4 equiv.),
DIEA (8 equiv.) in the minimal amount of DMF–DCM. After
45 min of incubation in the syringe reactor, the completeness of
the coupling reaction was checked by the Kaiser test.67
Cleavage of polymers. For the cleavage of all the structures
(with the exception of the c(RGDfK)–polymer), the dry resin
was treated with a TFA–H2O–TIS (95 : 2.5 : 2.5, v/v/v) mixture
for 1 h (10 mL g−1 resin). The resin was ﬁltered and washed
twice with DCM. After polymer cleavage, the solvent was evap-
orated. The product was precipitated in ice-cold tBME and the
precipitate was isolated by centrifugation. The pellet was dis-
solved in H2O–MeCN (1 : 1) and freeze-dried. Cleavage of the c
(RGDfK) polymeric scaffold ([Cys(trt)-Stp(Boc3)4]2-Lys–PEG–
Ala) from the resin was performed fully protected by incubating
the resin 5 times for 5 min with 10% HFIP in DCM. DCM was
subsequently evaporated.
The polymers were identiﬁed at λ = 220 nm by analytical
RP-HPLC (Waters 2998 photodiode array detector equipped
with the Waters 2695 separation module, Sunﬁre C4 column
(150 × 4.6 mm, 5 μm, 100 Å, Waters), and the Millenium soft-
ware; ﬂow rate = 1 mL min−1; gradient = 0–100% B in 15 min;
A = 0.045% TFA in H2O, B = 0.036% TFA in MeCN),
1H-NMR and high resolution mass spectra (LTQ-FT Ultra
(Thermo Scientiﬁc)).
Proton NMR spectra. 1H-NMR spectra were recorded using a
JNMR-GX 400 (400 MHz) or JNMR-GX 500 (500 MHz) unit
produced by Jeol. All spectra were recorded without tetramethyl-
silane (TMS) as internal standard and therefore all signals were
calibrated to the residual proton signal of the solvent. The coup-
ling constant had an accuracy of 0.3 Hz.
DNA polyplex formation. Polyplex formulations for transfec-
tion and gel shift experiments were prepared as follows: 200 ng
of pDNA and the calculated amount of polymer were diluted in
separate tubes each in 10 μL of 20 mM HEPES buffer with 5%
glucose pH 7.4 (HBG). The polycation solution was added to
the nucleic acid, rapidly mixed by pipetting up and down (at
least 5 times) and incubated for 30 min at RT in order to form
the polyplexes.
Transmission electron microscopy. Freeze-drying: Drops
(50 μL) of aqueous solutions of the polyplexes (200 μg pDNA
and polymer in a N/P ratio of 20) or free pDNA (20 μg μL−1)
were deposited on uncoated cover slips. These were then freeze-
ﬁxed by projection against a copper Cryoblock cooled by liquid
nitrogen (−196 °C) (Reichert-Jung, Leica, Germany). The frozen
samples were stored at −196 °C in liquid nitrogen until sub-
sequent use. Samples were freeze-dried at −90 °C and coated
with platinum and carbon by using a freeze-etching unit (model
BAF-060, BALTEC, Liechtenstein). Rotatory shadowing of the
exposed surface was performed by evaporating 1 nm of plati-
num–carbon at 6 °C above the horizontal plane, followed by
10 nm of carbon evaporated at 90 °C. The replica was separated
from the cover slip by immersion in concentrated hydroﬂuoric
acid, and was washed twice with distilled water and digested
with sodium hypochlorite (5%, v/v) for 5 to 10 min. The replicas
were washed several times in distilled water and collected on
Formvar-coated copper grids for electron microscopy. Negative
dye: Drops (50 μm) of aqueous solutions of the polyplexes
(200 μg pDNA and polymer in N/P ratio of 20) or free pDNA
(20 μg μL−1) were deposited on carbon ﬁlm-coated copper grids
for 1 min. After that, grids were washed (2 × 1 min) with water
and ﬁnally stained with 2% uranyl acetate (1 min). When the
grids were dry, electron micrographs were obtained. All micro-
graphs were obtained by using a Jeol JEM 1010 MT electron
microscope (Japan) operating at 80 kV. Images were obtained on
a CCD camera Megaview III (ISIS, Münster, Germany). The
results obtained by TEM imaging were found to be reproducible
within >50 (independent) measurements.
Atomic force microscopy (AFM). AFM imaging was per-
formed with a commercial multimode atomic force microscope
controlled by Nanoscope IV electronics (Digital Instruments).
10 μL of the sample were allowed to adsorb for 5–10 min at RT
on a freshly cleaved, highly ordered mica surface and ﬁnally
imaged in tapping mode operation.
DNA binding assay. A 1% agarose gel was prepared by dis-
solving agarose in TBE buffer (trizma base 10.8 g, boric acid
5.5 g, disodium EDTA 0.75 g, and 1 L of H2O) and boiling to
100 °C. After cooling to about 50 °C and addition of GelRed,
the agarose gel was cast in the electrophoresis unit. Polyplexes,
containing 200 ng of pDNA in 20 μL HBG and loading buffer
(prepared from 6 mL of glycerin, 1.2 mL of 0.5 M EDTA,
2.8 mL of H2O, 0.02 g of bromophenol blue) were placed into
the sample pockets. Electrophoresis was performed at 80 V for
80 min.
Measurement of particle size and zeta potential via dynamic
light scattering (DLS). Particle size of pDNA formulations and
zeta potentials were measured by laser-light scattering using a
Zetasizer Nano ZS (Malvern Instruments, Worcestershire, U.K.).
pDNA polyplexes with 10 μg pEGFPLuc were prepared in 1 mL
20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid) buffer pH 7.4 and measured after 30 min of incubation.
Ellman’s assay.68 0.4 mg of DTNB dissolved in 1 mL of the
corresponding Ellman’s buffer (0.2 M Na2HPO4 with 1 mM
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 3258–3268 | 3265
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EDTA at pH 8.0) was used as stock solution. For UV/VIS
absorption measurement Ellman’s stock diluted 1 : 10 in
Ellman’s buffer was taken as blank. Samples were diluted in
Ellman’s buffer and 10% (v/v) of the stock solution. After
15 min at 37 °C the solutions were measured at 412 nm. Concen-
trations of the free thiols at 0 min were set to 100%. For the
determination of free thiol groups over time, the polymer or
polyplex samples were processed as described above.
Cell culture. Mouse neuroblastoma cells (N2A) and human
prostate adenocarcinoma cells (DU-145) were obtained from
American Type Culture Collection ATCC (Rockville, MD,
USA). N2Awere grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) 4500 mg glucose L−1, supplemented with 10% FCS,
4 mM stable glutamine, 100 U mL−1 penicillin, and 100 μg
mL−1 streptomycin. DU-145 cells were grown in
RPMI-1640 medium supplemented with 10% fetal calf serum
(FCS), 4 mM stable glutamine, 100 U mL−1 penicillin, and
100 μg mL−1 streptomycin. Exponentially growing cells were
detached from the culture ﬂasks by using a trypsin–EDTA
(0.25%) solution and the cell suspension was seeded at the
required concentration for each experiment.
Gene transfer. Cells were seeded 24 h prior to pDNA delivery
using 10 000 cells per well in 96-well plates. Transfection
efﬁciency of the polymers was evaluated using 200 ng pEGF-
PLuc DNA per well. All experiments were performed in quintu-
plicate. At day of transfection medium was replaced with 80 μL
fresh medium containing 10% FCS. Transfection complexes
formed at various protonable nitrogen/phosphate (N/P) ratios in
20 μL HBG were added to each well and incubated at 37 °C.
After 1 h of incubation, the medium was removed and the cells
washed twice with phosphate-buffered saline (PBS). 90 μL of
fresh medium and 100 μM chloroquine in 10 μL PBS, 0.8 μg
suc-PEI in 10 μL PBS or 10 μL of PBS were added. In the case
of DU-145 cells, medium was removed again after 4 h and
replaced by fresh one. For the positive control, 0.8 μg of linear
PEI was mixed with pDNA (see pDNA polyplex formation
section) and polyplexes were treated the same way as all the
others. As negative control, cells were treated with 20 μL HBG
buffer. 24 h after transfection, cells were treated with 100 μL
cell lysis buffer (25 mM Tris, pH 7.8, 2 mM EDTA, 2 mM
DTT, 10% glycerol, 1% Triton X-100). Luciferase activity in the
cell lysate was measured using a luciferase assay kit (100 μL
Luciferase Assay buffer, Promega, Mannheim, Germany) and a
Lumat LB9507 luminometer (Berthold, Bad Wildbad,
Germany).
Transferrin and cilengitide competition assay. DU-145 cells
were seeded 24 h prior to pDNA delivery using 10 × 104 cells
per well in 96-well plates. Transfection efﬁciency of the poly-
mers in the presence or absence of transferrin (Tf) and cilengi-
tide was evaluated using 100 ng pEGFPLuc DNA per well. All
experiments were performed in quintuplicate. On the day of
transfection medium was replaced with 90 μL fresh medium con-
taining 10% FCS. The competing cells were incubated with
226 μg/well of iron-loaded (Fe-citrate, 1.25 μg mg−1 Tf) Tf
(human Tf from Sigma) or with 0.84 μg/well of cilengitide in
90 μL medium for 10 min at 4 °C in order to allow Tf and cilen-
gitide to bind to their corresponding receptors but preventing
from their internalization. Afterwards, transfection complexes
formed at N/P ratios of 6, 12 and 20 in 10 μL HBG were added
to each well and incubated at 37 °C. After 1 h of incubation, the
medium was removed and 100 μL of fresh medium containing
100 μM chloroquine were added. Medium was removed again
after 4 h and replaced by a fresh one. For the positive control,
0.8 μg of linear PEI was mixed with pDNA and polyplexes were
treated the same way as all the others. As negative control, cells
were treated with 10 μL HBG buffer. 24 h after transfection,
cells were treated with 100 μL cell lysis buffer (25 mM Tris, pH
7.8, 2 mM EDTA, 2 mM DTT, 10% glycerol, 1% Triton X-100).
Luciferase activity in the cell lysate was measured using the luci-
ferase assay kit. For the competition assay with increasing con-
centrations of Tf, the same protocol was followed with slight
modiﬁcations. DU-145 and N2A cells were seeded 24 h prior to
pDNA delivery using 10 000 cells per well in 96-well plates.
Transfection efﬁciency of the polymers in the presence or
absence of Tf was evaluated using 200 ng pEGFPLuc DNA per
well. At day of transfection medium was replaced with 80 μL
fresh medium containing 10% FCS. The cells were incubated
with no Tf, 90 or 226 μg iron-loaded Tf/well for 30 min at 4 °C.
Afterwards B6 transfection complexes formed at N/P ratio of 6
in 20 μL HBG were added to each well and incubated for 1 h at
37 °C. The medium was then removed and the cells washed
twice with PBS. 90 μL of fresh medium and 100 μM chloro-
quine in 10 μL PBS or 10 μL of PBS were added. Medium was
removed again after 4 h and replaced by a fresh one. For the
positive control, 0.8 μg of linear PEI was mixed with pDNA and
polyplexes were treated the same way as the experiment
described above. As negative control cells were treated with
20 μL HBG buffer. 24 h after transfection the luciferase
expression was measured as described before.
Cytotoxicity assay of polyplexes. N2A and DU-145 cells were
seeded into 96-well plates at a density of 1 × 104 cells/well.
After 24 h, culture medium was replaced with 80 μL fresh
growth medium containing 10% FCS and transfection complexes
(20 μL in HBG) at various N/P ratios were added. When chloro-
quine or suc-PEI was needed, it was added following the same
protocol used for the transfection experiments. All studies were
performed in quintuplicate. 22 h post transfection, 10 μl MTT
(5 mg mL−1) were added to each well reaching a ﬁnal concen-
tration of 0.5 mg MTT/mL. After an incubation time of 2 h,
unreacted dye and medium were removed. For cell lysis, samples
were frozen at −80 °C for 2 h. The purple formazan product was
dissolved in 100 μL/well dimethyl sulfoxide (DMSO) and quan-
tiﬁed by a microplate reader (Spectraﬂuor Plus, Tecan Austria
GmbH, Grödig, Austria) at 590 nm with background correction
at 630 nm. The relative cell viability (%) compared to control
cells containing cells treated with HBG was calculated by [A]
test/[A]control × 100.
Erythrocyte leakage assay. Murine erythrocytes were isolated
from fresh citrate-buffered blood and washed with PBS several
times. The erythrocyte pellet was diluted to 5 × 107 erythrocytes
per mL with PBS (pH 7.4, 6.5 and 5.5). Polymers were serially
diluted in 75 μL of PBS at concentrations of 7.5, 5 and 2.5 μM,
respectively, using a V-bottom 96-well plate (NUNC, Denmark).
For 100% lysis, control wells contained buffer with 1% Triton
3266 | Org. Biomol. Chem., 2012, 10, 3258–3268 This journal is © The Royal Society of Chemistry 2012
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X-100. A volume of 75 μL of erythrocyte suspension was added
to each well, and the plates were incubated at 37 °C under con-
stant shaking for 1 h. After centrifugation 80 μL of the super-
natant was analyzed for hemoglobin release at 405 nm using a
microplate plate reader (Spectraﬂuor Plus, Tecan Austria GmbH,
Grödig, Austria).
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